DOI: https://doi.org/10.22141/2224-0713.5.91.2017.110857
Dopamine receptor agonists in comprehensive pathogenetic therapy of Parkinson’s disease
Abstract
Keywords
Full Text:
PDF (Українська)References
Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group // JAMA. —
, Oct 18. — 284(15). — 1931-8.
Dopamine Transporter Brain Imaging to Assess the Effects of Pramipexole vs Levodopa on Parkinson Disease Progression // JAMA. —
— 287(13). — 1653-61.
Литвиненко И.В. и соавт. Боль и депрессия при болезни Паркинсона: новые терапевтические возможности прамипексола // Журнал неврологии и психиатрии им. С.С. Корсакова. — 2008. — 11. — С. 36-38.
Summary of the recomendations of the EFNS/MDS-ES review on the therapeutic management of Parkinson’s disease / Ed. by J. Ferreira, R. Katzenschlager, B. Bloem et al. // European Journal of Neurology. — 2013. — Vol. 20. — 5-15.
Aiken C.B. Pramipexole in psychiatry: a systemic review of the liter-ature // J. Clin. Psychiat. — 2007. — 68. — 1230-1236.
Corrigan M.H., Denahan A.Q. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression // Depress Anxiety. — 2000. — 11(2). — 58-65.
Barone P., Scarzella R., Marconi A., Antonini L., Morgante F., Bracco M., Zappia B. Musch and the Depression/Parkinson Italian Study Group. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease // Journal of Neurology. — 2006. — 253(5). — Р. 601-607.
Albert F.G. Leentjens, Jurgen Koester, Barbara Fruh et al. The effect of pramipexole on mood and motivational symptoms in Parkinson’s disease: a meta-analysis of placebo-controlled studies // Clinical Therapeutics. — 2009. — № 1.
Copyright (c) 2017 INTERNATIONAL NEUROLOGICAL JOURNAL

This work is licensed under a Creative Commons Attribution 4.0 International License.
© Publishing House Zaslavsky, 1997-2020
